Oculis Holding AG (OCS)
| Market Cap | 999.05M |
| Revenue (ttm) | 757,024 |
| Net Income (ttm) | -94.66M |
| Shares Out | 52.94M |
| EPS (ttm) | -2.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 70,617 |
| Open | 18.20 |
| Previous Close | 17.73 |
| Day's Range | 18.08 - 18.24 |
| 52-Week Range | 10.79 - 23.08 |
| Beta | 0.10 |
| Analysts | Strong Buy |
| Price Target | 30.25 (+60.31%) |
| Earnings Date | May 12, 2025 |
About OCS
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for ... [Read more]
Financial Performance
In 2024, Oculis Holding AG's revenue was 686,000, a decrease of -22.31% compared to the previous year's 883,000. Losses were -85.78 million, -3.41% less than in 2023.
Financial numbers in CHF Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for OCS stock is "Strong Buy." The 12-month stock price forecast is $30.25, which is an increase of 60.31% from the latest price.
News
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-o...
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-o...
Oculis Updates Share Capital
ZUG, Switzerland, April 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares o...
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award
ZUG, Switzerland, April 17, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro...
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets
ZUG, Switzerland, April 15, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophth...
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
ZUG, Switzerland, April 10, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro...
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
ZUG, Switzerland, April 10, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro...
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, April 09, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to directors of the Company.
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophth...
Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities
ZUG, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1...
Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update
ZUG, Switzerland, March 11, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophth...
Oculis to Present at Upcoming March Investor Conference
ZUG, Switzerland, March 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care...
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
ZUG, Switzerland, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthal...
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
ZUG, Switzerland, Feb. 08, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.
Oculis updates share capital for its existing at-the-market offering program
ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of...
Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care
Oculis' main value driver appears to be OCS-01, which targets a respectable $4 billion DME TAM with its non-invasive eye drops. Eye injections are tough on patients, so this bodes well for OCS-01. OCS...
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Cla...
Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities
ZUG, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The attached notification relates to a one-time equity incentive award issued to a director of the Company for his independent services as a consultant to the Co...
Oculis to Present at the Stifel 2024 Healthcare Conference
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announc...
Oculis Reports Q3 2024 Financial Results and Provides Company Updates
ZUG, Switzerland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and imp...
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees
ZUG, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announc...
Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024
ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announc...
Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board
SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune r...
Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer
ZUG, Switzerland, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announc...
Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award
ZUG, Switzerland, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, in collabora...